July 26, 2023
Action Requested
- Be aware that Candida auris (C. auris) has been identified in a patient in Washington.
- C. auris is an emerging often multidrug-resistant fungal pathogen and has caused outbreaks that are difficult to control in healthcare facilities outside of Washington.
- Be aware that strict adherence to routine healthcare infection prevention activities is effective in preventing spread of C. auris in healthcare facilities.
- Ensure your healthcare facility optimizes infection prevention practices that are proven to prevent transmission of C. auris, including hand hygiene, transmission-based precautions, environmental cleaning, and cleaning and disinfection of reusable medical equipment.
- Patients with suspected or confirmed C. auris in healthcare facilities should be managed using contact precautions and placed in a single room whenever possible.
- Reinforce and audit core infection prevention practices in healthcare facilities.
- When C. auris is suspected, use healthcare disinfectants that are effective against C. auris and follow disinfectant instructions for use including proper precleaning, dilution, and wet time.
- Remain vigilant for any increase in Candida results in a patient care unit, including from non-sterile sites, and consider C. auris. Review Candida speciation options with your lab. Candida isolates requiring speciation can be sent to the Washington Antibiotic Resistance Laboratory.
- Communicate information about colonization or infection with C. auris during care transitions within and transfers between healthcare settings. Consider using the CDC Interfacility transfer form.
- For laboratories working with suspect or confirmed C. auris, be aware of safety considerations including recommended PPE, disinfection, and disposal.
- Inquire about high-risk exposures in newly admitted patients and consider C. auris screening in patients at high-risk for C. auris, including those who have had:
- When risk factors for C. auris are identified, coordinate any C. auris screening and testing with Public Health. Testing at the public health lab requires preapproval from your local health jurisdiction (LHJ). Contact the Snohomish County Health Department at 425-339-3503 to reach the Communicable Disease program by phone.
- Be aware that Public Health offers proactive C. auris screening to residents at long-term ventilator capable healthcare facilities and long-term acute care hospitals.
- Be aware that C. auris can be misidentified through commercial laboratory testing and specific technology is needed for correct identification.
- Consider an infectious disease consultation for treatment options for patients with invasive C. auris infections. Even after treatment, patients generally remain colonized with C. auris for long periods, and perhaps indefinitely.
- Healthcare providers should immediately report suspected or confirmed C. auris cases or outbreaks in Snohomish County to the Snohomish County Health Department.
- Call 425-339-3503 to reach the Communicable Disease program by phone.
- Please complete and fax the Communicable Disease Report Form (PDF) and any accompanying lab reports to 425-339-8706.
- C. auris is a notifiable condition in WA as of January 1, 2023.
See full Washington DOH HAN alert for more information
Background:
A patient with a recent prolonged hospital stay at St. Joseph’s Medical Center in Tacoma was recently reported to have C. auris. Based on known details, it is believed that this case of C. auris was acquired locally. Information may change as the investigation proceeds. Washington State Department of Health (WA DOH) is also aware of one other unrelated state resident who tested positive for C. auris during a hospitalization in another state. WA DOH and partner local health jurisdictions are working with involved facilities to assess and optimize infection prevention practices and to perform screening of other patients to identify if transmission has occurred. Public Health is making this announcement to strongly encourage all healthcare facilities to optimize infection prevention practices and to prepare for safely admitting and caring for patients who are infected or colonized with C. auris.
C. auris was first reported in 2009 outside of the U.S. and has since emerged globally as a life-threatening, highly transmissible, often multidrug resistant yeast that has caused difficult to control healthcare outbreaks. Invasive infections with any Candida species can be fatal. Based on information from a limited number of patients, more than 1 in 3 people with C. auris infections have died. Patients needing long term acute care and indwelling devices are at the highest risk for acquisition. International healthcare is often the initial source of introduction of C. auris to a region and subsequent healthcare transmission may occur due to lapses in infection control practices.
C. auris can be misidentified as a number of different organisms when using traditional phenotypic methods for yeast identification such as VITEK 2 YST, API 20C, BD Phoenix yeast, and Microscan. An increase in infections due to unidentified Candida species in a patient care unit, including increases in isolation of Candida from urine specimens, should also prompt suspicion for C. auris.
DOH performs special surveillance for C. auris by screening isolates submitted from high-risk patients, proactive screening of patients in high acuity long term care facilities, and sentinel lab submissions of non-albicans Candida species to the WA Public Health Laboratory for species identification. There are currently no FDA-approved tests for colonization swabs. Laboratories with capability to characterize isolates further when C. auris is suspected are encouraged to do so. Public Health closely tracks all known C. auris cases and notifies healthcare facilities if a newly admitted patient should be screened.
Resources